News & Events

You are here

See Top 10 CRO article here

Asia-Pacific specialist CRO Novotech has been selected as one of the Top 10 CROs globally by leading industry media magazine Pharma Tech Outlook.

11/12/17

Novotech Update: Asia’s international clinical trial profile will continue to increase in 2018, says Novotech

Presenting at this year’s Outsourcing Clinical Trials East Asia 2017 in Seoul, Novotech CRO Chief Executive Officer Dr John Moller presented an overview on the opportunities and challenges of conducting multi regional clinical (MRCTs) trials in...

30/11/17

Novotech Update: Malaysian government invests in its early stage research industry and launches new Phase I clinical trial guidelines

Malaysia’s clinical trials industry body Clinical Research Malaysia (CRM) has launched the country’s first Phase I Clinical Trial Guidelines. The new guidelines present a standardised reference for First In Human (...

03/11/17

World Pharma Today: Increasing clinical trial competition within Asia to benefit sponsors says Novotech

In an article drafted for World Pharma Today, Novotech explains on how increasing clinical trial competition within Asia is of benefit to sponsors. 

...

03/11/17

World Pharma Today: Increasing clinical trial competition within Asia to benefit sponsors says Novotech

In an article drafted for World Pharma Today, Novotech explains on how increasing clinical trial competition within Asia is of benefit to sponsors. 

...

23/10/17

Novotech named a finalist in the 2017 Premier’s NSW Export Awards

Novotech has been named as a finalist in the Health and Biotechnology category of the upcoming 2017 Premier’s New South Wales Export Awards. 

“Novotech has had a terrific year of growth providing Australian clinical trial services to...

23/10/17

BioSpectrum Asia: Australia - A thriving lifescience hub with a global reach

In an interview with BioSpectrum Asia, Novotech CEO Dr John Moller provides his thoughts on the state of Australia's medical technologies, biotechnology and pharmaceutical (MTP) sector. ...

23/10/17

Novotech Update: China implements 5 key changes to accelerate clinical trial and drug approval timelines

With patients in China having to wait a minimum of six years to access medications already approved in Western markets, the combination of increasing disease burden and limited access to proven medication has resulted in growing pressure on the...

18/10/17

BioSpectrum India: Novotech remains very optimistic about the future of clinical trials in India

The Indian CRO market has undoubtedly contracted over the last few years following activity after the 2012 Supreme Court petition by the NGO Swasthya Adhikar Manch.

Since then the Indian government has worked...

16/10/17

Novotech wins ‘Australian Exporter of The Year’ at the India Australia Business Community Awards

Novotech has been awarded ‘Australian Exporter of The Year’ the 2017 Indian Australia Business Community (IABCA) Awards. 

India is a key market for Novotech, with the company first establishing its office in Bangalore in 2008. 

“By...

05/10/17

Novotech Update: Taiwan simplifies its First In Human regulatory process, reducing timelines by up to 3 months

The Taiwanese Ministry for Health and Welfare Food and Drug Administration (TFDA) recently announced it has simplified its First In Human (FIH) regulatory approval process; with the revised process reducing timelines from 120 days to just 30...

Pages